SF3B1 and myelodysplastic syndrome: In proven cases, specific mutations or comutations and the amount and type of mutations mostly tend to be unfavorable to the prognosis of MDS patients, with certain exceptions where SF3B1 mutation confers a superior outcome and prolonged survival [148–150].